(Q54152623)

Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Diabetic dyslipidaemia: insights for optimizing patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Thiazolidinediones and blood lipids in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

The cardiovascular effects of the thiazolidinediones: a review of the clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

PROactive Study: (r)evolution in the therapy of diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

The PROactive study: some answers, many questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Commentary: the PROactive study--the glass is half full

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Effect of ramipril on the incidence of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

Association of the metabolic syndrome and insulin resistance with silent myocardial ischemia in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.7.4.367

release_7nlvddwm25ewpijniacjuserla

21 January 2018

Identifiers

DOI

10.1517/14740338.7.4.367

0 references

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7nlvddwm25ewpijniacjuserla